StreetInsider.com News Articles

XWELL, Inc. (XWEL) files for 138.67M share offering by selling stockholders

Wed, 01 Apr 2026 17:14:44 -0400

XWELL, Inc. (NASDAQ: XWEL) has filed for up to 138,665,191 share offering by selling stockholders.

XWELL, Inc. (XWEL) files for 138.67M share offering by selling stockholders

Wed, 01 Apr 2026 17:14:44 -0400

XWELL, Inc. (NASDAQ: XWEL) has filed for up to 138,665,191 share offering by selling stockholders.

XWELL Reports Fiscal 2025 Results

Wed, 01 Apr 2026 16:30:00 -0400

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced financial results for the year ended December 31, 2025.

Recent Operating Highlights

XWELL delivered 2025 revenue of approximately $29.2 million.
Total operating expenses decreased by approximately 10% versus the comparable prior year period.
Cost of sales decreased approximately 13% versus 2024.
General and administrative expenses decreased approximately 20% year-over-year.
In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania

XWELL Reports Fiscal 2025 Results

Wed, 01 Apr 2026 16:30:00 -0400

Recent Operating Highlights

XWELL delivered 2025 revenue of approximately $29.2 million.
Total operating expenses decreased by approximately 10% versus the comparable prior year period.
Cost of sales decreased approximately 13% versus 2024.
General and administrative expenses decreased approximately 20% year-over-year.
In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania

XWELL Reports Fiscal 2025 Results

Wed, 01 Apr 2026 16:30:00 -0400

Recent Operating Highlights

XWELL delivered 2025 revenue of approximately $29.2 million.
Total operating expenses decreased by approximately 10% versus the comparable prior year period.
Cost of sales decreased approximately 13% versus 2024.
General and administrative expenses decreased approximately 20% year-over-year.
In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania

XWELL Reports Fiscal 2025 Results

Wed, 01 Apr 2026 16:30:00 -0400

Recent Operating Highlights

XWELL delivered 2025 revenue of approximately $29.2 million.
Total operating expenses decreased by approximately 10% versus the comparable prior year period.
Cost of sales decreased approximately 13% versus 2024.
General and administrative expenses decreased approximately 20% year-over-year.
In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania

Form SCHEDULE 13D XWELL, Inc. Filed by: American Ventures LLC, Series XXIV XWELL

Wed, 18 Mar 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260318/26187913.html

Form SCHEDULE 13D XWELL, Inc. Filed by: American Ventures LLC, Series XXIV XWELL

Wed, 18 Mar 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260318/26187913.html

Form SCHEDULE 13G XWELL, Inc. Filed by: McCabe James Joseph III

Wed, 11 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260311/26146119.html

Form SCHEDULE 13G XWELL, Inc. Filed by: McCabe James Joseph III

Wed, 11 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260311/26146119.html

Form 8-K XWELL, Inc. For: Feb 26

Wed, 04 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260304/26112738.html

Form 8-K XWELL, Inc. For: Feb 26

Wed, 04 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260304/26112738.html

Form D XWELL, Inc.

Tue, 03 Mar 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260303/26095605.html

Form D XWELL, Inc.

Tue, 03 Mar 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260303/26095605.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: WEINSTEIN ROBERT

Mon, 02 Mar 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260302/26094623.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: WEINSTEIN ROBERT

Mon, 02 Mar 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260302/26094623.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Lebowitz Michael

Mon, 02 Mar 2026 19:44:00 -0400

si-local-file:///var/storage/secattach/20260302/26094617.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Lebowitz Michael

Mon, 02 Mar 2026 19:44:00 -0400

si-local-file:///var/storage/secattach/20260302/26094617.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Bernstein Bruce

Mon, 02 Mar 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260302/26094611.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Bernstein Bruce

Mon, 02 Mar 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260302/26094611.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Ernst Ezra

Mon, 02 Mar 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260302/26094614.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Ernst Ezra

Mon, 02 Mar 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260302/26094614.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Wizenberg Gaelle Sandra

Mon, 02 Mar 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260302/26094604.html

Form 4 XWELL, Inc. For: Feb 27 Filed by: Wizenberg Gaelle Sandra

Mon, 02 Mar 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260302/26094604.html

AI Biotech, APAC Expansion, and Balance Sheet Rebuilds Set the Morning Tone

Wed, 25 Feb 2026 09:38:05 -0400

DENVER, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets. From micro-cap transformation stories to cash-rich TechBio platforms, this morning’s tape highlights companies positioning for scale in 2026 and beyond.

Totaligent Targets APAC Biologics and Medical Tourism

Totaligent (OTCID: TGNT) announced the execution of a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company, a Japanese medical aesthetics and biologics distributor, to form a joint venture integrating Totaligent’s recently announced Aetherium Medical platform.

The agreement establishes a JV